Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Jun;23(2):160-4.
doi: 10.1007/s11670-011-0160-x.

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma

Hong-Wei Zhang  1 , Niu-Liang Cheng, Zhen-Wen Chen, Jin-Fen Wang, Su-Hong Li, Wei Bai
Affiliations

Clinical Impact of t(14;18) in Diffuse Large B-cell Lymphoma

Hong-Wei Zhang et al. Chin J Cancer Res. 2011 Jun.

Abstract

Objective: Recent studies have suggested that t(14;18) is present in a significant proportion of diffuse large B-cell lymphomas (DLBCLs). However, the prognostic significance of this translocation and its relationship with BCL-2 protein expression remains controversial. Our study aimed to investigate the predictive power of t(14;18) and BCL-2 protein expression in the prognosis of DLBCLs.

Methods: Biopsy specimens from 106 DLBCLs were analyzed using interphase fluorescence in situ hybridization (FISH). Immunophenotypic analysis of CD20, CD3, CD10, BCL-6, MUM1 and BCL-2 was performed by immunohistochemistry. SPSS 13.0 software was used for statistical analysis.

Results: The t(14;18) was identified in 27 of 106 cases (25.5%). The percentages of tumor cells expressing CD10, BCL-6, MUM1 and BCL-2 were 21.7%, 26.4%, 56.6% and 73.6%, respectively. The presence of this translocation was significantly correlated with the expression of CD10 and immunophenotypic subtype (p<0.001). No association was observed between BCL-2 protein expression and the presence of t(14;18). Multivariate analysis confirmed that both t(14;18) and BCL-2 expression were significantly associated with survival. Moreover, patients with t(14;18) had worse prognosis, compared with those with BCL-2 expression (for overall survival: hazard ratio, 4.235; 95%CI, 2.153-8.329, p<0.001 vs. hazard ration, 2.743; 95%CI, 1.262-5.962, p=0.011).

Conclusions: The t(14;18) is a useful prognostic tool for the evaluation of DLBCL immunophenotype and prognosis. The prognosis of GCB (germinal centre-like B cell) DLBCL patients should be made with the consideration of the presence of this translocation, and the detection of t(14;18) should be included as a routine diagnostic test in these cases.

Keywords: 18), FISH, Survival analysis, Diffuse large B-cell lymphoma; Chromosome translocation, t(14.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Fluorescence in situ hybridization images obtained using a LSI IGH/BCL-2 dual-color and dual-fusion probe to detect the IGH/BCL-2 translocation. A, Nuclei of tumor cells without the IGH/BCL-2 translocation, showing two orange and two green signals, B, Within tumor cells with the IGH/BCL-2 translocation, one orange and one green with two yellow (orange +green fusion signal) signals were frequently observed in individual nuclei.
Figure 2
Figure 2
OS and PFS of patients with DLBCL, according to the t(14;18) status. A, Patients with t(14;18) showed poorer overall survival (OS) time than without t(14;18). B, Patients with t(14;18) showed poorer progression free survival (PFS) time than those without t(14;18).
Figure 3
Figure 3
OS and PFS of patients with DLBCL, according to the BCL-2 status. A, Patients with BCL-2-positive tumors showed poorer overall survival (OS) time than those with BCL-2-negative tumors. B, Patients with BCL-2-positive tumors showed poorer progression free survival (PFS) time than those with BCL-2-negative tumors.
See this image and copyright information in PMC

References

    1. Stein H, Warnke RA, Chan WC, et al. In WHO classification of tumors of haematopoietic and lymphoid tissues: diffuse large B-cell lymphoma, not otherwise specified. 4th ed. IARC: lyon, 2008.
    1. Jemal A, siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin 2007; 57: 43-66 - PubMed
    1. Gloeckler Ries LA, Reichman ME, Lewis DR, et al. Cancer survival and incidence from the Surveillance, Epidemiology, and End Results (SEER) program. Oncologist 2003; 8: 541-52 - PubMed
    1. Stewart BW, Kleihues P. In World Cancer Report. Lyon; IARC Press, 2003.
    1. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008; 9: 105-16 - PubMed